Rivastigmine (Exelon)

What it treats

Rivastigmine is approved by the U.S. Food and Drug Administration for mild to moderate Alzheimer's disease and for mild to moderate dementia associated with Parkinson's disease. It's the only cholinesterase inhibitor with a specific FDA approval for Parkinson's dementia, which is why it's often the first pick in that group.

It's also used off-label in Lewy body dementia and other dementias when a cholinesterase inhibitor is warranted.

Like the other drugs in this class, it's a symptomatic treatment. The goal is to slow decline, not reverse it.

How it works

Rivastigmine raises acetylcholine in the brain by blocking two enzymes that break it down. Extra acetylcholine helps the remaining nerve circuits work a little better in conditions where cholinergic neurons are dying off.

What sets rivastigmine apart from donepezil and galantamine is that it inhibits both acetylcholinesterase and butyrylcholinesterase. In late Alzheimer's disease the balance of these two enzymes shifts, and there's a theoretical argument that hitting both matters more as the disease progresses. In practice, head-to-head efficacy between the AChE inhibitors is broadly similar; the differences that actually matter for patients are tolerability and delivery.

Receptor mechanism (detail)

Rivastigmine is a pseudo-irreversible inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Blocking these enzymes raises synaptic acetylcholine, which acts at muscarinic and nicotinic receptors in the brain and body. The dual mechanism is the mechanistic argument for using it; the peripheral cholinergic effects are the source of the side effects.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Oral capsule: start at 1.5 mg twice daily with food. Increase by 1.5 mg twice daily every 2 to 4 weeks as tolerated. Target range is 3 to 6 mg twice daily. Total daily dose 6 to 12 mg. The oral form causes a lot of nausea and vomiting, which is why the patch has largely replaced it.

Transdermal patch: start at 4.6 mg per 24 hours for at least 4 weeks. If tolerated, step up to 9.5 mg per 24 hours (this is the usual maintenance dose). A 13.3 mg per 24 hour patch is available for people with moderate to severe disease. Rotate the application site (upper back, chest, upper arm) and don't reuse the same spot for at least 14 days.

Safety monitoring

• Heart rate and rhythm. Cholinesterase inhibitors slow the heart. Check pulse and consider an ECG in anyone with conduction disease or on rate-slowing drugs.
• Weight and appetite. Track weight at every visit. GI side effects can drive real weight loss.
• GI symptoms. Nausea, vomiting, and diarrhea are the classic complaints, especially with the oral form. Persistent vomiting is a reason to stop or switch.
• Skin reactions with the patch. Erythema, itching, and rarely allergic contact dermatitis at the application site. Site rotation is essential.
• Falls and syncope. New falls, dizziness, or fainting need a look at the drug.
• Interruptions in therapy. If the patch or capsule has been off for more than 3 days, restart at the lowest dose. Restarting at the maintenance dose can cause severe GI toxicity.

What to expect

Effect emerges gradually as a slower rate of decline. Over 3 to 6 months, families sometimes notice better attention or engagement compared to what they'd have expected. Formal cognitive scores drift down more slowly than they would without treatment. This is a stabilization drug, not a rescue drug.

With the oral form, GI side effects (nausea, vomiting, appetite loss) show up in the first weeks and are often the reason people stop. The patch is much easier to tolerate. Nausea rates are far lower and vomiting is uncommon. Trading the capsule for the patch is one of the most useful moves in the class.

Skin reactions at the patch site are the trade. Most are mild and manageable with rotation. A small number of people develop a true allergic reaction and can't stay on the patch.

Common side effects

The common side effects depend a lot on which form is being used.

Oral form:

• Nausea, often significant.
• Vomiting.
• Diarrhea.
• Loss of appetite and weight loss.
• Dizziness.
• Fatigue.

Patch form:

• Skin redness or itching at the application site.
• Mild nausea (much less than the capsule).
• Loss of appetite.
• Vivid dreams.
• Headache.

Serious side effects and warnings

• Severe GI toxicity with restart. If therapy is interrupted for more than a few days, restarting at the maintenance dose can cause severe vomiting, esophageal rupture in rare cases, and dehydration. Always restart at the starting dose.
• Bradycardia and syncope. Additive with beta blockers, verapamil, diltiazem, and digoxin.
• GI bleeding. Higher risk with NSAIDs or a history of ulcer.
• Weight loss. Clinically important in older adults with limited reserve.
• Skin allergy to the patch. Widespread rash or systemic reaction is a reason to stop.
• Seizures. Rare but reported.
• Urinary obstruction in people with existing bladder outlet issues.

Sexual and relational effects

Sexual side effects aren't a common complaint with rivastigmine. Libido shifts in dementia are usually driven by the disease itself, not by this drug. The bigger relational question is whether the drug helps caregivers manage day-to-day life. A modest bump in engagement or slower drift downward can matter a lot for families, and it's a reasonable thing to try for a defined trial period.

Weight, appetite, and sleep

Weight loss is a real concern, more so with the oral form. Appetite tends to dip in the first months and sometimes doesn't fully come back. Track weight and think about supplemental nutrition if the trend is meaningful.

Sleep effects are usually mild. Vivid dreams happen for some. The patch is worn for 24 hours, so timing isn't a lever the way it is with donepezil.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

The patch is applied once a day to clean, dry, hairless skin on the upper back, upper arm, or chest. Rotate sites so the same spot isn't reused for at least 14 days. Old patches should be folded sticky-side together and disposed of safely; they still contain drug that could be dangerous to a child or pet.

The oral form is taken twice daily with food. Both forms need slow titration to avoid GI trouble.

Missed doses and interactions

If a dose or patch is missed, apply the next patch at the usual time or take the next capsule at the usual time. Don't double up. If more than 3 consecutive days have been missed, contact the prescriber; restarting at the maintenance dose is dangerous.

Interactions that matter:

• Beta blockers, verapamil, diltiazem, digoxin. Additive bradycardia.
• Anticholinergics. Diphenhydramine, oxybutynin, older tricyclics, and similar drugs oppose rivastigmine and can worsen cognition. Common problem in older adults.
• NSAIDs. Higher GI bleeding risk.
• Succinylcholine. Prolonged neuromuscular blockade during anesthesia.
• Metoclopramide. Additive extrapyramidal risk in Parkinson's dementia.

Give every prescriber a full medication list.

Stopping and tapering

Rivastigmine doesn't cause a classic withdrawal, but stopping is often followed by a step-down in cognition or function within weeks that may not recover on restart. If the plan is to stop, tapering the patch strength down over a few weeks and watching for a change is safer than a hard stop.

Reasons to stop include intolerable side effects, advanced disease where the drug isn't helping meaningfully, and end-of-life care.

Pregnancy and breastfeeding

This isn't a routine issue given the patient population. Rivastigmine isn't used in pregnancy or breastfeeding in ordinary practice. Anyone in an unusual clinical situation involving reproductive planning should discuss it with a specialist.

Cost and generic availability

Generic rivastigmine capsules and generic transdermal patches are both available and inexpensive. Brand-name Exelon is still on the market but generally unnecessary. The patch tends to cost a bit more than the capsule but is worth it for tolerability.

Common questions

Why the patch instead of the capsule? Fewer GI side effects. That's the whole reason. The patch delivers the drug at a steadier rate and skips the peak levels that cause nausea and vomiting.

Is it better than donepezil? Similar overall benefit for Alzheimer's. Rivastigmine has the added FDA approval for Parkinson's dementia, and the patch is easier on the stomach than any oral cholinesterase inhibitor. That's the reason to pick it.

What if the skin gets irritated? Rotate sites carefully, moisturize the area (not the patch itself), and let the skin rest between applications. If irritation is persistent or spreading, tell the prescriber. Some people can't stay on the patch.

What happens if we miss a few days? Don't just restart at the maintenance dose. Call the prescriber. Restarting at a high dose after a break can cause severe vomiting.

Questions to ask your prescriber

• Is the patch or the capsule the right form for us?
• How will we track weight and heart rate?
• Are any of the current medications a problem with rivastigmine?
• What do we do if the patch causes skin irritation?
• How will we know when it's time to move up the dose, or time to stop?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Rivastigmine (Exelon) prescribing information.
• DailyMed, U.S. National Library of Medicine. Rivastigmine label.
• MedlinePlus, U.S. National Library of Medicine. Rivastigmine.
• National Institute of Mental Health. Mental health medications.
• American Academy of Neurology. Practice guideline update on pharmacologic treatment of dementia.
• American Psychiatric Association. Practice guideline on the use of antipsychotics and cognitive enhancers in dementia.